Veracyte (VCYT) Akcija Цена

Veracyte Цена

NASDAQ·ZATVORENO
25,13
​
Tržište je zatvoreno

U poslednjih 14 godina prihod Veracyte rastao je 45,8 % godišnje i dostigao 517,15 М USD. Za Veracyte neto marža od 12,8 % je porasla u odnosu na -34,4 % pre nekoliko godina. Konsenzusna 12-mesečna ciljana cena za Veracyte je 54,00 USD, oko iznad kurs za 114,9 %. Od 18 analitičara 16 preporučuje kupovinu — ukupni konsenzus je Kupi.

Cena akcije Veracyte

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Veracyte poslovni model i analiza akcije

Veracyte Inc je kompanija koja se specijalizovala za razvoj i marketing dijagnostičkih testova za širok spektar bolesti i poremećaja. Kompaniju je osnovao 2008. godine, a sedište joj se nalazi u Južnoj San Francisku u Kaliforniji. Istorija Veracyte Inc-a počinje sa vizijom da pomogne pacijentima pružanjem boljih opcija za dijagnozu. Kompanija je koristila svoje ekspertize u tehnologiji ekspresije gena kako bi razvila testove koji olakšavaju dijagnozu bolesti i poremećaja u različitim oblastima, kao što su rak, bolesti štitne žlezde i plućne bolesti. Poslovni model Veracyte Inc-a zasniva se na prodaji dijagnostičkih testova zdravstvenim ustanovama, bolnicama, lekarima i drugim medicinskim institucijama. Testove izvode stručno obučeni profesionalci i mogu pružiti preciznu dijagnozu koja pomaže lekarima da planiraju individualizovanu terapiju. Veracyte Inc je podeljen u različite odeljenja kako bi ponudio najbolji i najprecizniji test za svaku oblast. Odeljenja uključuju dijagnozu raka, dijagnostiku štitne žlezde, dijagnostiku pluća i druge oblasti tehnologije ekspresije gena. U dijagnostici raka, Veracyte Inc nudi testove za različite vrste raka, poput raka dojke, raka štitne žlezde i raka pluća. Testovi koriste sekvenciranje RNK za analizu genetske informacije pacijenata i pružaju precizniju dijagnozu. U dijagnostici štitne žlezde, Veracyte Inc nudi testove za različite bolesti štitne žlezde koje su često teško dijagnostikovati. Testovi pomažu u izbegavanju nepotrebnih hirurških intervencija ili medicinskih tretmana i omogućavaju pacijentima da dobiju tačniju dijagnozu i terapiju. U dijagnostici pluća, Veracyte Inc nudi testove za upalu pluća, rak pluća i druge plućne bolesti. Testovi koriste sekvenciranje RNK i slikovne metode kako bi pružili tačne dijagnoze koje pomažu lekarima da preporuče prilagođenu terapiju. Pored ovih odeljenja, Veracyte Inc takođe nudi druge proizvode i usluge, kao što su informativne kampanje i obuke za zdravstvene radnike, kao i podršku i savetovanje za pacijente i njihove porodice. U celosti, Veracyte Inc ima za cilj da revolucionira medicinsku oblast i pruži pacijentima bolje opcije za dijagnozu i terapiju. Testovi kompanije nude lekarima i pacijentima precizniju i personalizovanu dijagnozu, omogućavajući individualizovanu terapiju i postizanje najboljih rezultata.

Često postavljana pitanja o akciji Veracyte

The business model of Veracyte Inc is focused on providing genomic diagnostic tests to healthcare providers. Veracyte Inc utilizes advanced genomic technology to analyze patient samples and provide accurate diagnoses for various diseases, including cancer. By offering non-invasive and reliable diagnostic solutions, Veracyte Inc aims to improve patient care and outcomes. With its innovative and comprehensive testing portfolio, the company collaborates with physicians, researchers, and biopharmaceutical companies to enhance the understanding and treatment of complex diseases. As a leading genomic diagnostics company, Veracyte Inc is dedicated to transforming patient care through its precision medicine approach and cutting-edge technology.

Veracyte Inc is primarily active in the industry of molecular diagnostics.

The main competitors of Veracyte Inc in the market are companies like Genomic Health Inc, Myriad Genetics Inc, and NanoString Technologies Inc.

Veracyte Inc. is a renowned molecular diagnostics company with a rich history and background. Founded in 2008, Veracyte has been dedicated to improving patient outcomes by providing genomic testing solutions. Based in South San Francisco, California, the company combines advanced genomic technology with machine learning to deliver accurate and reliable diagnostic information to physicians and patients. Veracyte's innovative products, such as the Afirma Genomic Sequencing Classifier and Percepta Bronchial Genomic Classifier, have revolutionized the diagnosis of thyroid and lung cancers. Veracyte Inc. has grown rapidly over the years and continues to make significant contributions to the field of molecular diagnostics, benefiting countless patients and healthcare professionals alike.

Veracyte Inc has achieved significant milestones since its establishment. Notably, the company successfully launched the Afirma Genomic Sequencing Classifier, a groundbreaking diagnostic test used to detect thyroid cancer with high accuracy. Veracyte also received approval from the U.S. Food and Drug Administration (FDA) for its Percepta Bronchial Genomic Classifier, a test aiding in the diagnosis of lung cancer. Furthermore, the company expanded its product portfolio by introducing the Envisia Genomic Classifier, utilized for diagnosing idiopathic pulmonary fibrosis (IPF). Veracyte's commitment to innovative genomics and precision medicine has positioned itself as an industry leader, revolutionizing molecular diagnostic solutions for improved patient care.

Veracyte Inc primarily operates in the United States.

Veracyte Inc represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patient outcomes, the company combines cutting-edge genomic diagnostic solutions with machine learning to deliver accurate and actionable results. Veracyte Inc is committed to empowering physicians with reliable and timely information, helping them make informed decisions about patient care. The company's dedication to research and development ensures the continuous improvement of its products, leading to better diagnostic accuracy and personalized treatment options. Through its commitment to excellence and patient advocacy, Veracyte Inc is transforming the field of diagnostics and improving healthcare outcomes.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 55,57 USD za akciju Veracyte (medijana: 54,00 USD), što znači +121,9 % u odnosu na poslednju cenu. Konsenzus se zasniva na 18 ocena.

18 analitičara trenutno ocenjuje akciju Veracyte: 16 preporučuje kupovinu, 2 držanje i 0 prodaju. Za 2026 analitičari očekuju da Veracyte ostvari prihod 591,13 М USD i zaradu po akciji 1,91 USD.

Po trenutnom kursu akcija Veracyte kotira 22,89 EUR (25,13 USD).

Akcija Veracyte (VCYT) kotira na 4 berze, uključujući: NASDAQ (VCYT), Frankfurt (12V.F), München (12V.MU), Düsseldorf (12V.DU).

Veracyte Inc. is an emerging company specializing in the development of innovative diagnostic tests for cancer. The company's business model relies on a combination of technological innovation, close collaboration with medical professionals, and a strong distribution strategy. The products of Veracyte Inc. are designed to enable better diagnosis and therapy for cancer, thereby increasing the chances of cure. The company focuses on three main areas: endocrinology, lung cancer, and mesothelioma. Within endocrinology, Veracyte Inc. offers an innovative diagnostic procedure for thyroid nodules called the "Afirma Test," which allows for accurate differentiation between benign and malignant nodules without the need for surgery. This enables doctors to recommend targeted, non-invasive therapy and avoid unnecessary operations. In the field of lung cancer, the company has developed the "Percepta" test, which enables non-invasive diagnosis of lung cancer. The test uses RNA sequencing and analysis of protein content in lung fluid to make an accurate diagnosis of cancer cells. This allows for early diagnosis of lung cancer, increasing the chances of cure and avoiding unnecessary investigations and operations. The third area, mesothelioma, focuses on a rare form of cancer caused by asbestos exposure. Here, Veracyte Inc. offers the "Envisia" test, which enables accurate diagnosis of mesothelioma. The test uses specific markers and RNA sequencing to make an accurate diagnosis. Veracyte Inc. works closely with medical professionals and clinics to increase the acceptance and dissemination of its products. The company relies on a targeted distribution strategy and a strong online presence. By implementing targeted marketing and training for healthcare professionals and creating awareness among patients, the aim is to achieve broad acceptance of the products. In summary, the business model of Veracyte Inc. is based on the development of innovative diagnostic tests for various types of cancer. By collaborating closely with medical professionals and implementing a targeted distribution strategy, the company aims to increase the acceptance and dissemination of its products. The company is committed to increasing the chances of cure for cancer patients and avoiding unnecessary investigations and operations.

očekivana prihod od Veracyte je 591,13 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Veracyte je 155,18 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Veracyte je trenutno 13,18. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Veracyte.

Odnos cene i prihoda (KUV) za Veracyte je trenutno 3,46. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Veracyte.

Eulpool score kvaliteta za Veracyte je 6/10.

ISIN za Veracyte je US92337F1075. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Veracyte je A1W7EA. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Veracyte je VCYT. Simbol tikera se koristi za trgovinu akcijama Veracyte na berzanskom tržištu.

Фер вредностTerminal
24,88 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Биотехнологија
Број акција
Запослени
Приход по запосленом
684.960,26 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт veracyte.com
Валута
USD
Јавна понуда
30. окт 2013.
ISIN
US92337F1075
CUSIP
92337F107
SEDOL
BFTWZY0
Тржишна капитализација
Опсег од 52 недеље
AAQS
6 / 10
PEG
20,52
P/E однос
P/Ee 2026
13,05
P/Ee 2027
16,15
P/Ee 2028
14,93
P/Ee 2029
12,92
P/Ee 2030
12,11
P/S
P/Se
3,46
EV/EBIT
18,06
P/B однос
1,55
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
4,92 %
Zadnje ažurirano 21. нов 2026. 12:11

Veracyte Тикер

DISELORF · 12V.DUFRANKFURT · 12V.FMINHEN · 12V.MUNASDAQ · VCYT

Veracyte FIGI

VCYT:US · BBG001J2M542VCYT:UA · BBG005CHFWW5VCYT:UC · BBG005CHFWX4VCYT:UN · BBG005CHFWZ2VCYT:UP · BBG005CHFX08VCYT:UQ · BBG005CHFX17VCYT:UB · BBG005CHFX26VCYT:UM · BBG005CHFX44VCYT:UX · BBG005CHFX53VCYT:UD · BBG005CHFXC5VCYT:UF · BBG005CHFXG1VCYT:VY · BBG005CHFXH0

Sve ključne metrke i detaljne analize Veracyte u dubinskoj analizi

Naša analiza akcija za akciju Veracyte uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Veracyte. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: